+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

umbralisib

  • ID: 4775421
  • Report
  • 26 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Umbralisib (TG Therapeutics/Rhizen) is a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that also selectively inhibits casein kinase-1 (CK1) epsilon. Expression of the PI3K delta isoform plays a role in B-cell development and function, and is often overactivated in B-cell malignancies. Umbralisib has a unique chemical structure that confers greater specificity to target sites and may produce equivalent or improved efficacy, along with a more favorable safety profile, in comparison to other PI3K inhibitors such as Zydelig (idelalisib; Gilead) or Copiktra (duvelisib; Verastem) in non-Hodgkin’s lymphoma.

Analyst Outlook
TG Therapeutics is developing its phosphoinositide 3-kinase (PI3K) inhibitor umbralisib as part of a combination with its in-house cluster of differentiation (CD)20-targeted antibody, ublituximab. The combination is being evaluated in the Phase II/III UNITY-NHL trial (ClinicalTrials.gov identifier: NCT02793583) for the treatment of relapsed or refractory non-Hodgkin’s lymphoma (NHL) patients, including diffuse large B-cell lymphoma (DLBCL) patients. The combination has demonstrated early signs of efficacy, but significant adverse events potentially tied to PI3K inhibition, such as neutropenia, remain a concern. As such, umbralisib’s uptake may be limited by its side-effect profile, the potentially high cost of a combination regimen with ublituximab, and strong forecasted competition from approved regimens and several late-phase competitors targeting the relapsed or refractory patient segment.
Note: Product cover images may vary from those shown
2 of 2

OVERVIEW
Drug Overview
Product Profiles
umbralisib : NHL: Follicular lymphoma (FL)
umbralisib : NHL: Diffuse large B-cell lymphoma (DLBCL)

LIST OF FIGURES
Figure 1: Umbralisib for follicular lymphoma – SWOT analysis
Figure 2: The authors drug assessment summary of umbralisib for follicular lymphoma
Figure 3: Umbralisib sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26
Figure 4: Umbralisib for diffuse large B-cell lymphoma – SWOT analysis
Figure 5: The authors drug assessment summary for umbralisib in diffuse large B-cell lymphoma
Figure 6: Umbralisib sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Umbralisib drug profile
Table 2: Umbralisib ongoing pivotal trials in follicular lymphoma
Table 3: Umbralisib clinical trial data in follicular lymphoma
Table 4: Umbralisib sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 5: Umbralisib drug profile
Table 6: Umbralisib ongoing pivotal trial in diffuse large B-cell lymphoma
Table 7: Umbralisib sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country ($m), 2017–26

Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Order Online - visit: https://www.researchandmarkets.com/reports/4775421
Adroll
adroll